Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review.
暂无分享,去创建一个
M. J. van den Bent | M. Taphoorn | L. Dirven | J. Bromberg | M. van der Meulen | E. Habets | E. J. Habets
[1] P. Rojnuckarin,et al. Balancing relapses versus cognitive impairment in primary central nervous system lymphoma: a single-center experience , 2018, Hematology.
[2] F. Cavalli,et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. , 2017, The Lancet. Haematology.
[3] K. Ohtomo,et al. Combined intravitreal methotrexate and immunochemotherapy followed by reduced‐dose whole‐brain radiotherapy for newly diagnosed B‐cell primary intraocular lymphoma , 2017, British journal of haematology.
[4] O. Visser,et al. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015 , 2017, Leukemia.
[5] R. Fimmers,et al. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial , 2017, Journal of Cancer Research and Clinical Oncology.
[6] J. Panse,et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) , 2016, Leukemia.
[7] K. Hoang-Xuan,et al. Whole Brain Radiotherapy (WBRT) Versus Intensive Chemotherapy with Haematopoietic Stem Cell Rescue (IC + HCR) for Primary Central Nervous System Lymphoma (PCNSL) in Young Patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS) , 2016 .
[8] D. Brat,et al. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Y. Kanemura,et al. Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy. , 2016, Molecular and clinical oncology.
[10] Rose Anne Kenny,et al. Measurement Error, Reliability, and Minimum Detectable Change in the Mini-Mental State Examination, Montreal Cognitive Assessment, and Color Trails Test among Community Living Middle-Aged and Older Adults. , 2016, Journal of Alzheimer's disease : JAD.
[11] M. Pfreundschuh,et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. , 2016, The Lancet. Haematology.
[12] Volker W Stieber,et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.
[13] K. Hoang-Xuan,et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. , 2015, The Lancet. Haematology.
[14] D. Correa,et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. , 2015, Blood.
[15] I. Date,et al. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma , 2014, Clinical Neurology and Neurosurgery.
[16] M. Taphoorn,et al. The association between cognitive functioning and health-related quality of life in low-grade glioma patients. , 2014, Neuro-oncology practice.
[17] M. Taphoorn,et al. Tumour and surgery effects on cognitive functioning in high-grade glioma patients , 2014, Acta Neurochirurgica.
[18] A. Brandes,et al. MATILDE chemotherapy regimen for primary CNS lymphoma , 2014, Neurology.
[19] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[20] Dale F Kraemer,et al. Preservation of cognitive function in primary CNS lymphoma survivors a median of 12 years after enhanced chemotherapy delivery. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] D. Correa,et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] L. Maron,et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma , 2013, Neurology.
[23] A. Vincent,et al. Cognitive functioning early after surgery of gliomas in eloquent areas. , 2012, Journal of neurosurgery.
[24] D. Correa,et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. , 2012, Neuro-oncology.
[25] M. Taphoorn,et al. Compromised health-related quality of life in patients with low-grade glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] B. Scheithauer,et al. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. , 2011, International journal of radiation oncology, biology, physics.
[27] J. Villano,et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma , 2011, British Journal of Cancer.
[28] M. Reni,et al. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. , 2011, International journal of radiation oncology, biology, physics.
[29] E. Thiel,et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.
[30] R. Fimmers,et al. Long‐term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma , 2010, Annals of neurology.
[31] F. Cavalli,et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial , 2009, The Lancet.
[32] J. Reijneveld,et al. Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings , 2009, Journal of Neuro-Oncology.
[33] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[34] D. Correa,et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy , 2009, Journal of Neuro-Oncology.
[35] F. Feuerhake,et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system , 2008, Haematologica.
[36] D. Correa,et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] D. Correa,et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] Hideaki Takahashi,et al. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen , 2007, Leukemia & lymphoma.
[39] B. O'neill,et al. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. , 2004, International journal of radiation oncology, biology, physics.
[40] J. Armitage,et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] K. Fliessbach,et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma , 2005, Neurology.
[42] J. Cummings,et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.
[43] E. Neuwelt,et al. Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. , 2005, AJNR. American journal of neuroradiology.
[44] D. Nelson,et al. Secondary Analysis of Radiation Therapy Oncology Group study (RTOG) 9310: An Intergroup Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma , 2005, Journal of Neuro-Oncology.
[45] J. Menten,et al. Cognitive status and quality of life after treatment for primary CNS lymphoma , 2004, Neurology.
[46] D. Correa,et al. Cognitive functions in survivors of primary central nervous system lymphoma , 2004, Neurology.
[47] C. Pollack,et al. Intravenous Methotrexate as Initial Treatment for Primary Central Nervous System Lymphoma: Response to Therapy and Quality of Life of Patients , 1999, Journal of Neuro-Oncology.
[48] D. Osoba,et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma , 1997, Journal of Neuro-Oncology.
[49] N. Mackworth,et al. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores , 1992, Journal of Neuro-Oncology.
[50] R. Fimmers,et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] A. Zelenetz,et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] C. Meyers,et al. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] K. Hoang-Xuan,et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] K. Fliessbach,et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. , 2003, Archives of neurology.
[55] T. Batchelor,et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] L. Deangelis,et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] R. Fimmers,et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study , 2001, Journal of neurology, neurosurgery, and psychiatry.
[58] D. Kraemer,et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. , 2000, Neurosurgery.
[59] J. O'fallon,et al. The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group. , 1999, Neuro-oncology.
[60] D. Osoba,et al. Interpreting the significance of changes in health-related quality-of-life scores. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] R. Braziel,et al. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. , 1996, The cancer journal from Scientific American.
[62] M. Folstein,et al. Population-based norms for the Mini-Mental State Examination by age and educational level. , 1993, JAMA.
[63] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[64] R. Braziel,et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] A. Dobson,et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. , 1981, Journal of chronic diseases.
[66] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.